Spyre Therapeutics Analyst Ratings
Leerink Partners Initiates Spyre Therapeutics With Outperform Rating, $45 Price Target
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, Its Novel Half-life Extended IL-23 Antibody
Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target
Wolfe Research Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $27
Strategic Potential of Spyre Therapeutics in Combination Therapies for Inflammatory Diseases
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Hold Rating
Spyre Therapeutics Faces Compliance Hurdles After Transition From Smaller Reporting Company Status
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $65
Wedbush Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)
Buy Rating for Spyre Therapeutics Driven by Promising Drug Development and Strong Financial Position
TD Cowen Maintains Spyre Therapeutics(SYRE.US) With Buy Rating
Spyre Therapeutics Reports Strong Progress and Financial Stability
TD Cowen Keeps Their Buy Rating on Spyre Therapeutics (SYRE)
Spyre Therapeutics Q4 2024 GAAP EPS $(0.81) Beats $(1.01) Estimate
Express News | Spyre Therapeutics Inc Files for Mixed Shelf Offering of up to $500 Mln- SEC Filing
Spyre Therapeutics | 8-K: Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Spyre Therapeutics | 10-K: FY2024 Annual Report
Spyre Therapeutics Initiated With Early-stage Designation at Goldman Sachs